Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand

Phase 2

Terminated

• Conditions: Ovarian Cancer
• Interventions: Drug: EC-17

• Registration Number: NCT01511055
• Lead Sponsor: Mayo Clinic

Brief Summary

Prognosis for many carcinomas, including ovarian carcinoma, is dependent on a complete surgical resection, also known as a R0 resection. At present, the ability to perform a complete resection with negative margins is limited by the surgeon's ability to palpate and visualize the tumor and its margins. Therefore, in order to reduce operative morbidity and costs while maintaining or improving surgical and oncologic outcomes, the investigators must develop technologies that improve visualization of the primary tumor and occult metastases, real time, during surgery. Recent research has demonstrated that the use of fluorescent probes that recognize cancer specific antigens can be used for this purpose when visualized using a prototype near-infrared multispectral imaging system.

This investigation will determine if folate-FITC, a fluorescent probe that recognizes the folate receptor (present in \> 90% of ovarian cancers) can facilitate surgical resection and detect tumor nodules not visible to the naked eye.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-01
• Study First Submitted: 2012-01-12
• Study First Submitted QC: 2012-01-17
• Study First Posted: 2012-01-18
• Primary Completion: 2014-06
• Study Completion: 2014-06
• Disposition First Submitted: 2019-05-10
• Disposition First Submitted QC: 2019-05-10
• Disposition First Posted: 2019-05-15
• Results First Submitted: 2020-08-31
• Results First Submitted QC: 2020-09-21
• Status Verified: 2020-10
• Results First Posted: 2020-10-14
• Last Update Submitted: 2020-10-19
• Last Update Posted: 2020-11-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 27

Inclusion Criteria

Women who are:

• Diagnosed with or at high clinical suspicion of primary ovarian cancer by either radiologic imaging or physical examination or biopsy or serum tumor markers
• Scheduled to undergo surgical cytoreduction via laparotomy
• At least 18 years of age
• Capable and willing to provide informed consent

Read More

Exclusion Criteria

Women with:

• Known sarcomatous histologies
• Recurrent ovarian cancer
• Planned surgical approach via laparoscopy or robotic surgery
• A history of anaphylactic reactions to Folate-FITC or insects
• Inability or unwillingness to provide informed consent

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Folate-FITC	EC-17	-

Primary Outcome Measures

Name	Time	Method
Sensitivity and Specificity of Intra-operative Imaging Using Folate-FITC for Identification of Ovarian Cancer Metastatic to the Peritoneum and Lymph Nodes	1 week	A maximum of 5 nodules less than 1cm in size will be identified in each patient with the naked eye and then visualized with the camera. The nodules will be biopsied after determining if they are fluorescent positive or negative (F+ or F-), and examined microscopically to confirm if carcinoma is present. Up to 5 F+ lesions that were not identified with the naked eye will also be biopsied and examined microscopically to determine if carcinoma is present. These data will establish the sensitivity and specificity of this technique using microscopic analysis as the gold standard.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Grade 4 or Higher Adverse Events Following a One-time Dose of Folate-FITC (EC-17).	Duration of hospitalization with a maximum of 7 days	Study participants will be followed and all adverse events will be captured for the duration of hospitalization following administration of investigational product, up to a maximum of 7 days following IP administration and surgical procedure. Adverse Events will be classified as: grade 1=Mild, grade 2=Moderate, grade 3=Severe, grade 4=Life-threatening/disabling, grade 5 =Death. Significant is defined as adverse events grade 4 or higher.

Trial Locations

Locations (1)

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States